|本期目录/Table of Contents|

[1]程思杰,赵娜娜,严锦,等.长链非编码RNA LOC728290 在肝细胞癌患者肿瘤组织中的表达及意义[J].传染病信息,2018,02:121-124,139.
 CHENG Si-jie,ZHAO Na-na,YAN Jin,et al.Expression and significance of long non-coding RNA LOC728290 in tumor tissue of patients with hepatocellular carcinoma[J].Infectious Disease Information,2018,02:121-124,139.

长链非编码RNA LOC728290 在肝细胞癌患者肿瘤组织中的表达及意义(PDF)




Expression and significance of long non-coding RNA LOC728290 in tumor tissue of patients with hepatocellular carcinoma
100039 北京,解放军第三〇二医院肝胆外科中心 (程思杰、赵娜娜、严锦、王瑞兰、余灵祥、肖朝辉、雷光林、 张培瑞、王兆海、张绍庚、杨鹏辉)
CHENG Si-jie ZHAO Na-na YAN Jin WANG Rui-lan YU Ling-xiang XIAO Chao-hui LEI Guang-lin ZHANG Pei-rui WANG Zhao-hai ZHANG Shao-geng* YANG Peng-hui*
Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, China
hepatocellular carcinoma long non-coding RNA clinical significance
目的 探讨肝细胞癌(hepatocellular carcinoma, HCC)患者肿瘤组织中长链非编码RNA(long non-coding RNA, LncRNA)LOC728290 的表达及其临床意义。方法 应用实时荧光定量PCR(real-time quantitative PCR, qRT-PCR)检 测HCC 患者手术切除的癌组织及其配对癌旁组织中LncRNA LOC728290 的表达水平;统计分析其表达水平与患者临床病理 特征之间的相关性,同时结合患者生存时间及预后随访情况,分析LncRNA LOC728290 表达水平和无复发生存率之间的 关系。结果 83%(54/65)HCC 患者癌组织中LncRNA LOC728290 的表达量较配对癌旁组织下调(P < 0.05);LncRNA LOC728290 的表达水平在不同AFP 水平、有/ 无微脉管浸润的患者中,呈显著差异表达(P < 0.05);生存分析表明 LncRNA LOC728290 表达水平低的HCC 患者无复发生存率较其表达水平高的患者显著降低(P < 0.05)。结论 LncRNA LOC728290 在HCC 患者肿瘤组织中呈显著低表达,其有望成为临床HCC 早期诊断、转移及预后评估的潜在分子标志物和 治疗靶标。 
Objective To determine the expression of long non-coding RNA (LncRNA) LOC728290 in tumor tissue of hepatocellular carcinoma (HCC) patients and explore its clinical significance. Methods The expression level of LncRNA LOC728290 in surgically resected tumor tissues and adjacent non-tumor tissues of HCC patients was detected by using quantitative real-time PCR, and its correlation with clinicopathological characteristics was analyzed. Meanwhile, the correlation between LncRNA LOC72829 expression and recurrence-free survival was analyzed based on the survival period and prognosis follow-up. Results The expression of LncRNA LOC728290 in tumor tissues of 83% (54/65) HCC patients was significantly decreased compared with that in adjacent non-tumor tissues (P < 0.05). A significant difference was observed in LncRNA LOC728290 expression among patients with different levels of serum AFP and patients with or without microvascular invasion (P < 0.05). Survival analysis displayed that the recurrence-free survival rate in patients of lower expression of LncRNA LOC72829 was significantly decreased compared with that of high expression of LncRNA LOC72829 (P < 0.05). Conclusions LncRNA LOC72829 is significantly lowly expressed in tumor tissue of HCC patients. It may provide a potential molecular marker and therapeutic target for early clinical diagnosis and evaluating the metastasis and prognosis in HCC. 


[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics[J]. CA Cancer J Clin, 2015, 65(2):87-108.
[3] Saha SK, Parachoniak CA, GhantaKS, et al. Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer[J]. Nature, 2014, 513(7516):110-114.
[4] Protzer U. Hepatitis: epigenetic control of HBV by HBx protein- -releasing the break[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(10):558-559.
[5] Zhu M, Guo J, et al. Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells[J]. Oncotarget, 2015, 6(14):12196-12208.
[6] Zavattari P, Perra A, Menegon S, et al. Nrf2, but not beta-catenin, mutation represents an early event in rat hepatocarcinogenesis[J]. Hepatology, 2015, 62(3):851-862.
[7] Gauglhofer C, Paur J, Schrottmaier WC, et al. Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma[J]. Carcinogenesis, 2014, 35(10): 2331-2338.
[8] Necsulea A, Soumillon M, Warnefors M, et al. The evolution of lncRNA repertoires and expression patterns in tetrapods[J]. Nature, 2014, 505(7485):635-640.
[9] Ponting C, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs[J]. Cell, 2009, 136(4):629-641.
[10] Fitzgerald KA, Caffrey DR. Long noncoding RNAs in innate and adaptive immunity[J]. Curr Opin Immunol, 2014, 26:140-146.
[11] He X, Bao W, Li X, et al. The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis[J]. Int J Mol Med, 2014, 33(2):325-332.
[12] Martens-Uzunova ES, Bottcher R, Croce CM, et al. Long noncoding RNA in prostate, bladder, and kidney cancer[J]. Eur Urol, 2014, 65(6):1140-1151.
[13] Du Z, Sun T, Hacisuleyman E, et al. Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer[J]. Nat Commun, 2016, 7:10982.
[14] Wan L, Sun M, Liu GJ, et al. Long non-coding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression[J]. Mol Cancer Ther, 2016, 15(5):1082.
[15] Zhai W, Sun Y, Jiang M, et al. Differential regulation of LncRNASARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2alpha/C-MYC axis under hypoxia[J]. Oncogene, 2016, 5(Suppl 1):S4866.
[16] Yang F, Zhang L, Huo XS, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans[J]. Hepatology, 2011, 54(5):1679-1689.
[17] Yuan JH, Yang F, Wang F, et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma[J]. Cancer Cell, 2014, 25(5):666-681.
[18] Lechel A, Gougelet A. Early HCC treatment: a future strategy against interferon/miR-484 axis to revert precancerous lesions[ J]. Gut, 2016, 65(7):1703-1704.
[19] Iguchi T, Uchi R, Nambara S, et al. A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer[J]. Anticancer Res, 2015, 35(3):1385-1388.
[20] Qiu JJ, Lin YY, Ding JX, et al. Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer[J]. Int J Oncol, 2015, 46(6):2497-2505.
[21] Yue B, Qiu S, Zhao S, et al. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis[J]. J Gastroenterol Hepatol, 2016, 31(3):595- 603.
[22] Luo F, Sun B, Li H, et al. A MALAT1/HIF-2alpha feedback loop contributes to arsenite carcinogenesis[J]. Oncotarget, 2016, 7(5):5769-5787.
[23] Panzitt K, Tschernatsch MM, Guelly C, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA[J]. Gastroenterology, 2007, 132(1):330-342.
[24] Ohrnberger S, Thavamani A, Braeuning A, et al. Dysregulated serum response factor triggers formation of hepatocellular carcinoma[J]. Hepatology, 2015, 61(3):979-989.
[25] 王福生,李元元,史继静,等. 直接抗病毒药物对慢性丙 型肝炎特殊人群的治疗进展[J]. 传染病信息,2017, 30(2):70-74.
[26] Li J, Chen Z, Tian L, et al. LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma[J]. Gut, 2014, 63(11):1700-1710.
[27] Thum T. Noncoding RNAs and myocardial fibrosis[J]. Nat Rev Cardiol, 2014, 11(11):655-663.
[28] Zhang S, Chen S, Yang G, et al. Long noncoding RNA HOTAIR as an independent prognostic marker in cancer: a meta-analysis[J]. PLoS One, 2014, 9(8):e105538.
[29] Carr BI, Guerra V, Giannini EG, et al. Significance of platelet and AFP levels and liver function parameters for HCC size and survival [J]. Int J Biol Markers, 2014, 29(3):e215-e223.
[30] Dwyer JP, Hosking P, Lubel J. Multiple liver lesions in a patient with positive hepatitis C serology and elevated AFP: is it HCC [J]. Gastroenterology, 2014, 147(3):e12-e13.
[31] Li T, Xie J, Shen C, et al. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma[J]. Oncogene, 2016, 35(12):1575.
[32] Li T, Xie J, Shen C, et al. Amplification of long noncoding RNA ZFAS1 promotes metastasis in hepatocellular carcinoma[J]. Cancer Res, 2015, 75(15):3181-3191.


[基金项目] 北京市自然科学基金(7162185)
[通信作者] 杨鹏辉,E-mail: ypenghuiamms@hotmail.com;张绍庚, E-mail: zhangsg302@hotmail.com
更新日期/Last Update: 2018-03-20